Drug Search Results
More Filters [+]

Cetuximab sarotalocan

Alternative Names: Cetuximab sarotalocan, rm-1929, rm1929, rm 1929, ASP-1929, ASP1929, ASP 1929
Latest Update: 2024-09-27
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: EGFR Inhibitor

Novel Mechanism: No

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Rakuten Medical
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cetuximab sarotalocan

Countries in Clinic: India, Japan, Taiwan, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Head and Neck Cancer

Phase 2: Squamous Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ASP-1929-301

P3

Recruiting

Head and Neck Cancer

2025-12-01

ASP-1929-103

P2

Active, not recruiting

Head and Neck Cancer|Squamous Cell Carcinoma

2024-07-11

ASP-1929-181

P2

Active, not recruiting

Head and Neck Cancer|Squamous Cell Carcinoma

2024-06-01

57%

Recent News Events